---
document_datetime: 2025-05-28 16:25:03
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lacosamide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lacosamide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.3172075
conversion_datetime: 2025-12-22 10:26:43.156624
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lacosamide Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,please alsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber      | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amended on   | Product Information affected3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | B.II.b.1Replacementor additionof a | 28/05/2025                          |                                           | Annex II and                    |           |

1Notifications areissuedfortypeIvariations andArticle61(3)notifications(unlesspartofagroupincludinga typeIIvariationorextensionapplicationoraworksharingapplication).Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),Annex II,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annex II, labelling,package leaflet).The CDisissuedwithintwomonthsof theopinionforvariationsfallingunderthescopeofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000274929   | manufacturingsiteforpartor all of the manufacturingprocess of thefinished product - B.1I.b.1.a Secondary packaging site-Accepted B.II.b.2.cReplacementoradditionofa manufacturerresponsibleforimportation and/or batch release - B.11.b.2.c.2 Including batchcontrol/testing-Accepted A.5Change in thename and/or address of a manufacturer/importer of the finished product(includingbatchreleaseorquality control testing sites)-A.5.b The activities for which the manufacturer/importer is responsible donotincludebatchrelease- Accepted A.5Changeinthename and/or address of a manufacturer/importer of the finished product(includingbatchrelease or quality control testing sites)-A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   | PL   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

<div style=\"page-break-after: always\"></div>

| reagent or excipient (when mentioned in the dossier)*- Accepted   |
|-------------------------------------------------------------------|